Clinical Trial Update: IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for IdeS in asymptomatic antibody-mediated thrombotic thrombocytopenic purpura (TTP) has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• IdeS (Immunoglobulin-degrading enzyme of Streptococcus pyogenes)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: Purpura, Thrombotic Thrombocytopenic | Phase 2 | Status: TERMINATED | Results posted: 2019-09-13